Comparing Sera Prognostics (SERA) & Its Competitors

Sera Prognostics (NASDAQ:SERA – Get Rating) is one of 45 public companies in the “Medical laboratories” industry, but how does it weigh in compared to its competitors? We will compare Sera Prognostics to similar companies based on the strength of its dividends, valuation, earnings, analyst recommendations, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Sera Prognostics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	0	1	4	0	2.80
Sera Prognostics Competitors	353	1095	1761	47	2.46

Sera Prognostics presently has a consensus target price of $18.50, indicating a potential upside of 1,117.11%. As a group, “Medical laboratories” companies have a potential upside of 105.96%. Given Sera Prognostics’ stronger consensus rating and higher probable upside, research analysts clearly believe Sera Prognostics is more favorable than its competitors.

Earnings and Valuation

This table compares Sera Prognostics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sera Prognostics	$80,000.00	-$35.01 million	-0.35
Sera Prognostics Competitors	$1.09 billion	$56.91 million	8.03

Sera Prognostics’ competitors have higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

63.2% of Sera Prognostics shares are held by institutional investors. Comparatively, 61.5% of shares of all “Medical laboratories” companies are held by institutional investors. 20.1% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Sera Prognostics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-38,185.05%	-58.37%	-30.80%
Sera Prognostics Competitors	-1,687.27%	-37.96%	-17.61%

Summary

Sera Prognostics competitors beat Sera Prognostics on 8 of the 12 factors compared.

Sera Prognostics Company Profile (Get Rating)

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Want More Great Investing Ideas?